DMD and Thrombocytopenia: Clinical trials with dystrophin exon 51 skipping 2OMePS antisense oligonucleotides (AONs) have reported improvements in DMD however, they were also accompanied by some side effects e.g. proteinuria and moderate thrombocytopenia, that hampered progress32–34.